7159 Loss of work activity and productivity in caregivers attending to patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alfa: evaluations from a phase 3 randomized trial

Phase 3 ◽

Work Activity

7160 Evaluation of adverse event -related hospitalizations in patients with advanced renal cell carcinoma on treatment with temsirolimus or interferon-alfa: results from a phase 3 randomized trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71493-4 ◽

2009 ◽

Vol 7 (2) ◽

pp. 441

Author(s):

S. Rajagopalan ◽

E. Pullenayegum ◽

E. Alemao ◽

A. Strahs ◽

J. Purvis

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Event ◽

Randomized Trial ◽

Cell Carcinoma ◽

Renal Cell ◽

Interferon Alfa ◽

Phase 3

PCN126 LOSS OF WORK ACTIVITY AND PRODUCTIVITY IN CAREGIVERS ATTENDING TO PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH TEMSIROLIMUS OR INTERFERON-ALFA: EVALUATIONS FROM A PHASE 3 RANDOMIZED TRAIL

Value in Health ◽

10.1016/s1098-3015(10)74377-1 ◽

2009 ◽

Vol 12 (7) ◽

pp. A281 ◽

Cited By ~ 1

Author(s):

S Yang ◽

E Alemao

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Interferon Alfa ◽

Phase 3 ◽

Work Activity

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M, Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN), Medizinische Hochschule Hannover, Germany.

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2004.07.002 ◽

2004 ◽

Vol 22 (5) ◽

pp. 432

Author(s):

Donald L. Trump

Keyword(s):

Renal Cell Carcinoma ◽

Randomized Trial ◽

Cell Carcinoma ◽

Renal Cell ◽

Renal Carcinoma ◽

Interleukin 2 ◽

Interferon Alfa ◽

7134 Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71467-3 ◽

2009 ◽

Vol 7 (2) ◽

pp. 433 ◽

Cited By ~ 3

Author(s):

S. Yang ◽

G. Hudes ◽

P. deSouza ◽

E. Alemao ◽

A. Strahs ◽

...

Keyword(s):

Quality Of Life ◽

Renal Cell Carcinoma ◽

Randomized Trial ◽

Cell Carcinoma ◽

Renal Cell ◽

Interferon Alfa ◽

Phase Iii ◽

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M, Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN), Medizinische Hochschule Hannover, Germany.J Clin Oncol 2004;22:1188–94

Urologic Oncology Seminars and Original Investigations ◽

10.1016/s1078-1439(04)00143-7 ◽

2004 ◽

Vol 22 (5) ◽

pp. 432-432

Author(s):

D TRUMP

Keyword(s):

Renal Cell Carcinoma ◽

Randomized Trial ◽

Cell Carcinoma ◽

Clin Oncol ◽

Renal Cell ◽

Renal Carcinoma ◽

Interleukin 2 ◽

Interferon Alfa ◽

Faculty Opinions recommendation of Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1119981.576105 ◽

2008 ◽

Author(s):

Sharokh Shariat ◽

Jose Karam

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Interferon Alfa ◽

Faculty Opinions recommendation of Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13484037.14861147 ◽

2012 ◽

Author(s):

Thomas Powles

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Comparative Effectiveness ◽

Phase 3

TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma

SSRN Electronic Journal ◽

10.2139/ssrn.3427299 ◽

2019 ◽

Author(s):

Brian Rini ◽

Sumanta K. Pal ◽

Bernard J. Escudier ◽

Michael B. Atkins ◽

Thomas E. Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study

Re: Comparative Effectiveness of Axitinib versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial

The Journal of Urology ◽

10.1016/j.juro.2012.04.069 ◽

2012 ◽

Vol 188 (2) ◽

pp. 412-413

Author(s):

Samir S. Taneja

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Comparative Effectiveness ◽

Phase 3

Re: Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

European Urology ◽

10.1016/j.eururo.2008.09.037 ◽

2009 ◽

Vol 55 (1) ◽

pp. 250-252 ◽

Cited By ~ 3

Author(s):

Shahrokh F. Shariat ◽

Jose A. Karam ◽

Pierre I. Karakiewicz

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Interferon Alfa ◽